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The area of life science is very dynamic and flexible. For example,
Aldous Huxley had already such a symbolic novel“Brave New World”
in connection with in-vitro-fertilization in1932,and recently,we have
 
just known a new symbolic invention of“induced pluripotent stem cell
(＝iPS Cell)”by Prof.Shinya Yamanaka of Kyoto University in Japan
 
in 2007, by which we have had just possibilities to use “regenerative
 
medicine”or“tissue engineering”without breaking human embryos like
 
in case of using “embryonic stem cell(＝ES Cell)”. And then many
 
efforts are being made to overcome the risk of cancer which will derive
 
from the technique of iPS Cell.
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(Note)
＊ This paper is one that I have reported in the 5? ICCEC (International
 
Conference of Clinical Ethics and Consultation)in Taipei(Academia Cinica),12
March 2009and modified after that. In this International Conference, I must
 
thank for Professor Michael Cheng-tek Tai (Chun Shan Medical University,
Taiwan)who gave us various hospitalities.
＊＊ Professor Dr.,Waseda Law School,Waseda University.
In the post genome era,it may be disadvantages for mankind that the
 
law too strongly regulates scientific and medical activities in this field
 
because it can obstruct the progress of life science or medicine.There-
fore on the one hand,it is true that the freedom of study and research
 
is guaranteed by the Art.23of the Constitution in Japan.But on the
 
other hand,we must carefully examine whether this freedom is unlim-
ited or not. Prof. Koichi Bai, who is the founder of medical law in
 
Japan,had already pointed out some important fundamental perspec-
tives on this aspect in 1974;
1)awareness of the limit of legal intervention into natural facts and
 
progresses of natural science,
2)role of law in adjusting conflict between one interest and the other
 
interest,and





These perspectives seem to me very useful also today. We must
 
consider the balance between promotion of life science or medical
 
science and protection of human right in this field. Thus we must
 
rethink how we should regulate illegal misconducts in this field.On this
 
point,also Prof.Dr.Albin Eser,who is one of the most famous scholar
 
of medical law in Germany,had expressed similar opinions in1984,and
 
recently proposes a global theory. In his theory, he insists that we
 
should change our paradigm from“Sektorales Medizinrecht”(Sectoral
 




2006.I agree with his opinion.
(１) Koichi Bai, Kagaku to Ho to Seimei to (Science, Law and Life), in
 
Takamine Matsuo (Ed.), Seimeikagaku Noto (in Japanese) (Life Science
 
Note),1974,Tokyo University Press,p.197ff.especially pp.200-201.
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In connection with these perspectives, in this paper, I will show a
 





２ Objects of Regulation
 
We can classify objects of regulation into three categories.The first is
 
objects to regulate clearly; e. g. crimes, social harmful conducts
(trafficking), abuse of eugenics, genetic discrimination, and human
 
cloning (not including therapeutic cloning).We should legally prohibit
 
these conducts due to such harmfulness to our society,and therefore
 
impose criminal sanction on these conducts.
The second is objects to promote;e.g.genome research.Naturally,
it needs due process in going on the study plan,but it is not necessary
 
to regulate it legally.
The third is objects to be permitted with certain conditions;e. g.
(２) Albin Eser,Perspektiven des Medizin (straf)rechts. In:Wolfgang Frisch
(ed.), Gegenwartsfragen des Medizinstrafrechts (in German),2006, pp. 9-31.
This article is translated into Japanese by Katsunori Kai/ Yoshinori Fu-
kuyama,in Katsunori Kai(Ed.),Posuto Genomu Shakai to Ijiho(in Japanese)
(Post-Genome Society and Medical Law),2009,Shinzansha,p.31ff.,and Kenji
 
Ueda/Kazushige Asada (Ed.), Ijikeiho kara Tougoutekiijiho e (in Japanese)
(Von Medizinstrafrecht zu integrativem Medizinrecht),2011,Seibudo,p.265ff.
(３) See in detail Katsunori Kai,Seimeikagaku to Hoteki Ruru (Life Science
 
and Legal Rule), in Waichiro Iwashi/Toru Masui/Yasuko Shirai/Tomoko
 
Hasegawa/Katsunori Kai,Kogi:Seimeikagaku to Ho(in Japanese)(Lecture:
Life Science and Law),2008,Shogakusha,p.191ff.;Katsunori Kai,Hikakuhote-
ki Kanten kara mita Sentaniryo/Igakukenkyu no Kisei no Arikata(Model of
 
Regulation to Medical Innovation and Medical Researchfrom the Viewpoint
 
ofComparative Law),Katsunori Kai(Ed.),supra,note(3),Post-Genome Soci-
ety and Medical Law,p.190ff.
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therapeutic cloning,use of ES-cell,stem cell and iPS-cell.As we cannot
 
concretely foresee any risks and results, we should watch these
 
researches with certain conditions.We can hope that they may bring
 
about possibilities to cure some curable diseases in near future.In my
 
opinion,it is appropriate that the UK Report of House of Lord(2002)
has already declared this direction.Also in Japan recently,this direc-
tion has been officially confirmed.Naturally,also it needs due process
 
in going on the study plan,but it is not necessary to regulate it legally.
３ Grounds of Regulation
 
What can we think about the ground of regulation? In my opinion,
firstly, it should be based on “Human Dignity”(Menschenwu?rde in
 
German), which derives from German philosopher Immanuel Kant.
“Human Dignity”is“Sein mit Menschen-Dasein”and should be behind
 
human being,human tissues,corpse,and human embryo.
However the problem of ownership or property on his/her body
 
conflicts with “Human Dignity”.Generally speaking, libertalianism is
 
affirmative to ownership or property on his/her
(４)
body. But it seems
 
strange to me to grasp human body as property.We should consider
 
human body rather in connection with“Human Dignity”.
Then what should we think about criminal regulation?In my opinion,
criminal regulation should be the last measure (ultima ratio). There
 
are some fundamental principles in applying criminal law.Incidentally,
(４) So also Jean-Pierre Baud,L’affaire de la main vole?e.Une histoire juridi-
que du corps, Paris, Édition du Seuil, 1993 (This book is translated into
 





Japanese criminal law has been strongly influenced from German
 
criminal law.
The first principle is “Tatprinzip”(Conduct-principle in English).
According to this principle,we cannot punish a conduct without certify-
ing an external harmful conduct. It includes causation. In Anglo-
American jurisdiction,it is concerned with actus reus.
The second principle is “Nulla poena sine lege, nullum crimen sine
 
lege”(No penalty without law,no crime without law).According to
 
this principle,we cannot punish a conduct without a clear provision of
 
law.
The third principle is “Schuldprinzip ”(Nulla poena sine culpa;No
 
penalty without culpability). According to this principle, we cannot
 
punish a conduct without intention or negligence,and criminal responsi-
bility).In Anglo-American jurisdiction,it is concerned with mens rea.
These three principles should be considerated also in the field of
 
medical or life science.At least,we should use criminal sanction in such
 
cases where people feel or have vague and slight misgivings alone in
 
this field.
４ Model of Regulation
 
Then what should we think about model of regulation?We can classify
 
it into three categories.The first is the hard law style like in Germany.
The German “Embryonen Schutzgesetz”(Protection of Embryo Act)
1990) is typical of it because it is a special criminal law. I think,
however, that German legal system is not suitable for regulation to
 
medical and scientific field because it is too hard to keep up flexibly
 
with the trend of life science.Indeed in Germany,“Gesetz zur Sicher-
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stellung des Embryonenschutzes im Zusammenhang mit Einfur und
 
Verwendung menschlicher embryonaler Stammzellen ＝Stammzell-
gesetz―StZG)has been enacted in 2002(revised in 2008),and by this
 
law, they have been able to use human stem cell for research in
 
Germany.However it seems strange to me that they can use only stem
 
cell which is imported from foreign countries.
The second is the soft law style like in Japan.We have many official
 
guidelines in this field in Japan; for example, Ethics-Guideline for
 
Human-Genome/ Gene Analysis Research (2001, revised 2004 by
 
Ministry of Education, Culture, Sports, Science and Technology;
Ministry of Health,Labour and Welfare;Ministry of Economy,Trade
 
and Industry),and the Guideline for the Protect of Personal Informa-
tion for Business Operations Handling Personal Genetic Information
(2004;Ministry of Economy,Trade and Industry). The latter is the
 
guideline for buisiness (except use for research), which includes 1)
informed consent by documents, 2)genetic counseling, 3)setting up
 
committee,4)specifying strictly the aim of use,5)prohibition of getting
 
sensitive information, 6)risk management including anonymity of
 
materials,7)general prohibition of providing it to the third party,8)
withdrawal of consent,9)setting up the window for consultations.
However, these guidelines have no legal sanctions, therefore they
 
cannot ensure more effectiveness to exclude remarkable abuses. As
 
they are so-called a kind of?patch work”,we cannot understand the
 
fundamental viewpoint.Thus this model is not enough suitable in this
 
field although they are flexible.
The third is the mixed style of the hard and soft law like in UK and
 
Australia etc..The Human Fertilisation and Embryology Act1990(＝
HFEA 1990)and the Human Tissue Act 2004in UK are typical of it,
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and furthermore they are supplemented by some guidelines.According
 
to this model,we can normally correspond with various new medical
 
and scientific technologies and problems.
Thus as a result of comparative study,in Japan,we should aim at this
 
mixed type between hard law and soft law.And yet,we should consider
“the Legal Doctrine of Medical Due
(５)
Process”.This is a legal theory
 
which I have insisted for a long time.According to this theory,as a rule,
medical innovation/medical research without due process is unlawful.
Medical Due Process contains (1) informed consent, (2) balancing
 
between risks and benefits, (3) due review by appropriate ethical
 
committee,and(4)compensation to human subjects system because we
 
cannot foresee concrete risks.Furthermore(5)it contains some excep-
tional legal sanctions against extreme abuses.Due to this doctrine,we
 
can build a bridge between law, bioethics and medical and scientific
 
research and practice. I think that we can realize it by enacting the
 
Fundamental Law of Bioethics in Japan.
５ Conclusion
 
Nowadays we are faceed with some concrete problems in this field.For
 
example,problems of genetic information are very important.Recently,
the ?Genetic Information Nondiscrimination Act”of 2008(＝GINA)
has been enacted in USA.It contains the prohibition of genetic informa-
tion discrimination in health,insurance and employment.And in Swit-
zerland,?Budesgesetz u?ber Genetische Untersuchung beim Menschen”
has been enacted in 2004(2007 enforcement). Also it contains very
(５) See Katsunori Kai,Hikensha Hogo to Keiho(in Japanese)(Protection of
 
Human Subjects and Criminal Law),2005,Seibudo,Tokyo,p.7f.and 30ff.
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important and very stimulating provisions in Art.1,2,4,5,6etc..In the
 
Netherlands,?Wet op de medische keuningen”has been already enact-
ed in1997,which contains a very important provision of Art.3.Also in
 
Austria,?Gentechnik-Gesetz”has been already enacted in1994,which
 
contains a very important provision of Art.67.
To the contrary,in Germany,a suggestion of legislation concerning
 




2002, but such a legislation has not been easily realized.
However in 2009, the new Act “Gesetz u?ber genetische Untersuchung
 
beim Menschen (Gendiagnostikgesetz)”has been
(７)
concluded. In Aus-
tralia,there are only Guidelines
(８)
on it.
Nowadays we should trans-nationally consider the problems of
 
genetic information because the biobank system has become more and
 
more important in the
(９)
world.The first thing we should have to do is to
 
make the Fundamental Law of Bioethics in Japan in harmonization
 
with foreign countries. We are now preparing this draft with Prof.
Ryuichi Ida (Kyoto
(10)
University). Concerning to important points in
(６) Deutscher Bundes Referat Öffentlichkeit (Hrsg.), Enquete-Kommission.
Recht und Ethik der Modernen Medizin.Schlussbericht(in German),2002.This
 
book is translated into Japanese by Prof. Jun Matsuda (Superviser), 2004,
Chisen Shokan.
(７) See Katsunori Kai,“Gesetz u?ber genetische Untersuchung beim Menschen
(Gendiagnostikgesetz)”in Germany,in Medical Law Vol.25(2010),p.197ff.
(８) Don Chalmers,The Governance of Biobanks and Databases for Research－
Towards an International Consensus on Ethical Principles,Taiwan Journal of
 
Law and Technology Policy,Vol.4No.1(2007),p.5ff.
(９) To legal system of biobank in detail,see Jasper A.Bouvenberg,Property
 
Rights in Blood,Genes and Data,the Netherlands,2006.
(10) See Ryuichi Ida,Seimeirinri to Ho:Wagakui ni okeru Seimeirinrikihonho
 
no Teigen (in Japanese) (Bioethics and Law in Post-Genome Society: A
 
Proposal of the Fundamental Law of Bioethics in Japan),in Kai(Ed.),supra,
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bioethics,we should make a fundamental legal system.The Fundamen-
tal Law of Bioethics will be in the center of bioethics.Thus I think it
 
is better that the model of regulation on medical innovation/medical
 
research should be the mixed type of hard law and soft law,that is to
 
say, four steps which consist of public guideline (＝soft law), civil
 
regulation,administrative regulation,and lastly criminal regulation(＝
hard law).
On this model of regulation, I try to approach to issues on
(11)
neuroscience,nanotechnology and robotics from now on.
note(3),Post-Genome Society and Medical Law,p.211ff.
(11) To issues of neuroscience,see Katsunori Kai,Neurolaw in Japan,in Tade
 
Mattias Spranger (Ed.), International Neurolaw－A Comparative Analysis,
2011,Springer Verlag,Heidelberg (in printing).
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